BCR/ABL1 qRT PCR, minor
Expected Turnaround Time
7 days
Stated turn-around-times (TATs) are for clinical use only and subject to change based on biopharma protocol requirements. Final TATs will be specified in the biopharma study contract.
Stated turn-around-times (TATs) are for clinical use only and subject to change based on biopharma protocol requirements. Final TATs will be specified in the biopharma study contract.
Clinical Information
Quantitative reverse transcriptase polymerase chain reaction (qRT-PCR) for the detection of the minor BCR::ABL fusion gene transcript p190 (e1a2) in patients with a Philadelphia (t[(9;22)(q34;q11.2)]) positive leukemia. The minor fusion type p190 (e1a2) is commonly associated with ALL.
Requisition Forms
Specimen Requirements
Specimen Requirements
- Whole Blood: 10 mL (minimum 5mL), EDTA preferred (NaHep accepted)
- Bone Marrow Aspirate: 3 mL (minimum 1 mL), EDTA preferred (NaHep accepted)
Specimen Stability
Specimen must be received by MPLN within 48 hours of collection.
Storage Requirements
2-8°C
Shipping Recommendations
REFRIGERATED, Protect from extreme temperature with ice pack. Separate ice pack from specimen.
Specimen Rejection Criteria
Specimen >48 hours old; Specimen clotted; Specimen stored or shipped at incorrect temperature; Specimen in incorrect anticoagulant; Insufficient specimen volume; Isolated RNA of suboptimal quantity and/or quality
Test Details
Synonyms
Philadelphia Chromosome; minor t(9;22) e1 (p190)
Keywords
Leukemia, Molecular Diagnostics, Oncology, Acute Lymphoblastic Leukemia (ALL), Chronic Myelogenous Leukemia (CML), Quantitative PCR, Genomics
Test Method
Quantitative reverse transcriptase polymerase chain reaction (qRT-PCR)
Methodology Category
Molecular
Regulatory Status
RUO
Special Considerations
- Frozen blood samples are NOT accepted.
- Please notify MPLN if shipment is to arrive after 1 p.m. Friday or Saturday.
Associations
Chronic myelogenous leukemia (CML), Acute lymphoblastic leukemia (ALL), Allogeneic bone marrow transplantation, Minimal residual disease (MRD), Molecular remission, Tyrosine Kinase Inhibitors